

Familial Breast Cancer GC3 minutes

Familial Breast Cancer update – guideline committee meeting 3 minutes

Date: 09/04/2026

Location: Virtual

Minutes: Final

Committee members present:		
Alison Cameron	Chair	Present for items 1-9
Kay Davies-Crowley	Advanced Nurse Specialist	Present for items 1- partway through 6
Zoe Kemp	Clinical Geneticist	Present for items 1-9
Sarah Pugh	Genetic Counsellor	Present for items 1-9
Kathryn Rigby	Breast Surgeon	Present for items 1-9
Tamsin Sargeant	Lay member	Present for items 1-9
Hannah Seabrook	Clinical Psychologist	Present for items 1-9
Liz Sherwin	Clinical Oncologist	Present for items 1-9

In attendance NICE:		
Sarah Boyce	Senior Technical Analyst	Present for items 1-9
Victoria Carter	Implementation Lead	Present for items 6-9
Danielle Conroy	Project Manager	Present for items 1-9
Lina Ford	Technical Analyst	Present for items 1-9
Gareth Haman	Senior Guidance Content Designer	Present for items 1-8
Marie Harrisingh	Topic Lead	Present for items 1-9
Tzujung Lai	Health Economist	Present for items 1-9
Lea Mansour	Health Economist (observing)	Present for items 1-5, 7-9
Yolanda Martinez	Technical Analyst	Present for items 1-9
Eric Slade	Health Economics Adviser	Present for items 1-9
Nicky Welton	Technical Support Unit (observing)	Present for items 6- partway through 7

Apologies:	
Rachael Griffin	Co-opted Lay member, committee
Helen Hanson	Clinical Geneticist, committee
Sadaf Haque	General Practitioner, committee

Ashley Hurst	Lay member, committee
Adam Storrow	Resource Impact, NICE

1. Welcome, Introductions and apologies

The Chair, Alison Cameron (AC) welcomed the committee members and NICE attendees to the 3rd committee meeting for the NICE Familial Breast Cancer guideline update which will focus on initial assessment, genetic testing and risk reducing mastectomy.

AC informed attendees that apologies had been received as noted above and the minutes from committee meeting 2 were checked and agreed to be an accurate record.

2. Declaration of interests

AC asked all committee members to verbally declare any new interests.

No new interests were declared but AC reminded committee of the following recorded interest which is relevant to the day's discussion.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Zoe Kemp	Consultant in Cancer Genetics and Breast Medical Oncology, Royal Marsden Hospital	Participation in the BRCA BCY Collaboration (international, hospital-based, retrospective cohort study). Publications from collaboration: Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study Lancet Oncology 2025 Jun;26(6):759-770	Specific, Direct -non-financial professional and personal	Declare and partial exclusion Participate in discussion but withdraw for drafting recommendations.

Zoe Kemp (ZK) was author on a paper included in an evidence review being discussed. It was agreed that she could remain in the room to answer questions and participate in discussion of the evidence as her expertise was required but she would need to remain silent whilst recommendations on risk-reducing mastectomy were being drafted or revised.

3. RQ5: effectiveness of risk-reducing mastectomy in people at increased risk of heritable breast cancer:

- **Recap of clinical evidence**
- **Recap of cost effectiveness evidence**
- **Committee discussion of evidence**

The Chair introduced Lina Ford (LF), Technical Analyst who provided a recap of the effectiveness evidence for risk-reducing mastectomy which was presented at the last meeting along with the results of 4 new studies which have been identified for inclusion.

Tzujung Lai (TZ), Health Economist then provided a summary of the cost-effectiveness evidence in this area.

The committee had the opportunity to consider and discuss the evidence in its entirety before moving on to recommendation drafting.

The Chair thanked LF and TZ for their input.

4. Recommendation drafting for RQ5

The Chair introduced Marie Harrisingh (MH), Topic Lead, who led the committee discussion on the draft recommendations they had started at the previous meeting to consider whether any amendments or additions were required.

ZK remained silent and did not participate in this agenda item unless to answer questions for which her expertise was required in this area.

5. Recommendation drafting for RQ5 continued

After a short break the committee continued to review, discuss and draft recommendations.

ZK remained silent and did not participate in this agenda item unless to answer questions for which her expertise was required in this area.

6. Discussion about subgroup analyses for RQ1

The Chair introduced Sarah Boyce (SB), Senior Technical Analyst, who asked for committee input on several outstanding queries on the review protocol for carrier probability assessment models.

The committee had the opportunity to discuss as a group and offer their expert input on questions relating to subgroups and which versions of diagnostic prediction models should be included in the review.

The NICE team will make edits to the review protocol based on committee's decisions today.

The Chair thanked SB for her input.

7. RQ2&3: carrier probability at which germline genetic testing should be offered to people with:

- a personal history of breast cancer
- without breast cancer who are suspected to have a heritable predisposition to breast cancer
- Health economic modelling

The Chair introduced Eric Slade (ES), Health Economics Adviser, who provided an update on the economic modelling for this update.

ES presented an overview of the proposed health economic model. The committee discussed various model assumptions, including age and gene-specific cancer risks, genetic testing uptake in relatives, the effectiveness of surveillance, risk reducing surgery uptake and utility data.

The committee provided their expert views on the most appropriate data sources for these model inputs.

The NICE team will start modelling based on committee's feedback today.

The Chair thanked ES and the committee for their input.

8. Recommendation drafting for RQ5 continued

The group returned to finishing drafting recommendations with the remaining time of the meeting.

ZK remained silent and did not participate in this agenda item unless to answer questions for which her expertise was required in this area.

With support from the committee, the NICE team were able to revise initial wording and make additional recommendations in this area, including recommendations for research, which will be taken away for further edits.

The Chair thanked MH and the committee for their input.

9. AOB and close

AC summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, AC brought the meeting to a close.

Date of next meeting: 19th May 2026

Location of next meeting: Virtual